Mitoxantron "ebewe" (Mitoxantrone)

Mitoxantrone intercalates into DNA and stabilises the DNA‑topoisomerase II complex, preventing the enzyme from resealing DNA strands after cleavage. This leads to accumulation of DNA breaks, cell‑cycle arrest and ultimately apoptosis of rapidly proliferating cancer cells.

The dose of mitoxantrone is individualized and set by the prescribing oncologist based on the specific indication, patient characteristics, disease stage and treatment protocol. Clinicians determine the appropriate amount and schedule for each patient.

Mitoxantrone is classified as having an unknown pregnancy category and is generally avoided during pregnancy and lactation because of potential fetal toxicity and the risk of adverse effects in the infant. Use only if the potential benefit justifies the risk.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with traditional anthracyclines, mitoxantrone has a similar mechanism of DNA intercalation but a distinct toxicity profile, showing lower incidence of acute cardiotoxicity but a notable risk of delayed cardiac effects and secondary leukemia. Choice of agent depends on disease type, prior therapy and patient risk factors.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original packaging until use, and handled with appropriate protective equipment to avoid skin contact or inhalation of the solution.

Mitoxantron ebewe is supplied as an intravenous solution and is administered by a qualified healthcare professional through a controlled IV infusion. The infusion rate and duration are determined by the treating physician according to the prescribed regimen.

The most serious risks include cardiotoxicity that can lead to irreversible heart damage, the development of secondary acute leukemia, and severe infections resulting from profound neutropenia. Patients should be monitored closely for cardiac function, blood counts and signs of infection.

Mitoxantrone is contraindicated in patients with known hypersensitivity to the drug or its excipients, in those with uncontrolled cardiac disease, and in pregnant or nursing women unless the potential benefit outweighs the risk. Caution is also advised for patients with severe hepatic impairment.